Bone-targeted therapy in metastatic breast cancer - All well-established knowledge?

Breast Care

Volumn 9, Issue 5, 2014, Pages 323-330

  Gampenrieder, Simon P ^a   Rinnerthaler, Gabriel ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Bisphosphonates; Bone metastasis; Bone targeted therapy; Denosumab; Metastatic breast cancer

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB;

ANTINEOPLASTIC ACTIVITY; BONE TARGETED THERAPY; BONE TURNOVER; BREAST METASTASIS; DISEASE MARKER; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84913620525     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000368710     Document Type: Review

References (70)

1. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
2. Delea T, McKiernan J, Brandman J, et al.: Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-347.
3. Costa L, Badia X, Chow E, et al.: Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16:879-889.
4. Norgaard M, Jensen AO, Jacobsen JB, et al.: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010;184:162-167.
5. Coleman RE: Bisphosphonates in breast cancer. Ann Oncol 2005;16:687-695.
6. Russell RG: Bisphosphonates: the first 40 years. Bone 2011;49:2-19.
7. Brown JE, Coleman RE: Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 2012;9:110-118.
8. Lipton A, Fizazi K, Stopeck AT, et al.: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-3092.
9. Body JJ, Diel IJ, Lichinitzer M, et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase iii studies. Br J Cancer 2004;90:1133-1137.
10. Kohno N, Aogi K, Minami H, et al.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
11. Lipton A, Theriault RL, Hortobagyi GN, et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
12. Theriault RL, Lipton A, Hortobagyi GN, et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854.
13. Tripathy D, Lichinitzer M, Lazarev A, et al.: Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004;15:743-750.
14. Wong MH, Stockler MR, Pavlakis N: Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Reviews 2012;2:CD003474.
15. Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
16. Barrett-Lee P, Casbard A, Abraham J, et al.: Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014;15:114-122.
17. Major P, Lortholary A, Hon J, et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
18. Rosen LS, Gordon D, Kaminski M, et al.: Longterm efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
19. Rosen LS, Gordon DH, Dugan W Jr, et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
20. Coleman RE: Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol 2002;25:S25-31.
21. Hortobagyi GN, Lipton A, Chew HK, et al.: Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the optimize-2 trial. J Clin Oncol 2014;32:5s.
22. Dougall WC, Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006;25:541-549.
23. Coleman R, Gnant M, Morgan G, Clezardin P: Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104: 1059-1067.
24. Henry DH, Costa L, Goldwasser F, et al.: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.
25. Stopeck AT, Lipton A, Body JJ, et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
26. Fizazi K, Carducci M, Smith M, et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
27. Henry D, Vadhan-Raj S, Hirsh V, et al.: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 2014;22:679-687.
28. Coleman RE, Major P, Lipton A, et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
29. Lipton A, Cook R, Saad F, et al.: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201.
30. Fizazi K, Lipton A, Mariette X, et al.: Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-1571.
31. Clezardin P: Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011;48:71-79.
32. Neville-Webbe HL, Gnant M, Coleman RE: Potential anticancer properties of bisphosphonates. Seminars in oncology 2010;37 Suppl 1:S53-65.
33. Stresing V, Fournier PG, Bellahcene A, et al.: Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011;48: 259-266.
34. Stresing V, Daubine F, Benzaid I, et al.: Bisphosphonates in cancer therapy. Cancer Lett 2007;257: 16-35.
35. Tang X, Zhang Q, Shi S, et al.: Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 2010;126:90-103.
36. Gallo M, De Luca A, Lamura L, Normanno N: Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 2012;23:597-604.
37. Fata JE, Kong YY, Li J, et al.: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103:41-50.
38. Gonzalez-Suarez E, Jacob AP, Jones J, et al.: Rank ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103-107.
39. Tan W, Zhang W, Strasner A, et al.: Tumourinfiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011;470:548-553.
40. Santini D, Schiavon G, Vincenzi B, et al.: Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PloS One 2011;6:e19234.
41. Misso G, Porru M, Stoppacciaro A, et al.: Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther 2012;13:1491-1500.
42. Chlebowski RT, Chen Z, Cauley JA, et al.: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28: 3582-3590.
43. Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28:3577-3581.
44. Aft R, Naughton M, Trinkaus K, et al.: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-428.
45. Rack B, Juckstock J, Genss EM, et al.: Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30:1807-1813.
46. Solomayer EF, Gebauer G, Hirnle P, et al.: Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012;23:2271-2277.
47. Banys M, Solomayer EF, Gebauer G, et al.: Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 2013;13:480.
48. Coleman R, Gnant M, Paterson A, et al.: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. Cancer Res 2013;73(24 suppl):abstr S4-07.
49. Cook RJ, Hirsh V, Major PP, et al.: Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): survival in patients with high bone turnover. J Clin Oncol 2008; 26:abstr 20562.
50. Dearnaley DP, Mason MD, Parmar MK, et al.: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009;10:872-876.
51. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al.: The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-1709.
52. Smith MR, Saad F, Coleman R, et al.: Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46.
53. Mortimer JE, Pal SK: Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol 2010;37(suppl 1):S66-72.
54. Saad F, Brown JE, Van Poznak C, et al.: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: ntegrated analysis from three blinded activecontrolled phase iii trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-1347.
55. Weitzman R, Sauter N, Eriksen EF, et al.: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol 2007;62:148-152.
56. Block GA, Bone HG, Fang L, et al.: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27:1471-1479.
57. Wang W, Wang EQ, Balthasar JP: Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-558.
58. Kreutle V, Blum C, Meier C, et al.: Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. Swiss Med Wkly 2014;144: w13979.
59. Milat F, Goh S, Gani LU, et al.: Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. Bone 2013;55:305-308.
60. Paul D, Vukelja SJ, Holmes FA, et al.: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Cancer Res 2013;73(24 suppl):abstr S3-07.
61. Campone M, Bondarenko I, Brincat S, et al.: Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol 2012;23:610-617.
62. Jensen AB, Wynne C, Ramirez G, et al.: The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, doubleblind, randomized, controlled trial. Clin Breast Cancer 2010;10:452-458.
63. Hadji P, Coleman R, Gnant M: Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol 2013;87:101-111.
64. Onishi T, Hayashi N, Theriault RL, et al.: Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 2010;7:641-651.
65. Deng X, He G, Liu J, et al.: Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev 2014;40:730-738.
66. Parker C, Nilsson S, Heinrich D, et al.; ALSYMPCA Investigators: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-223.
67. Coleman R, Aksnes AK, Naume B, et al.: A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat 2014;145: 411-418.
68. Rubini G, Nicoletti A, Rubini D, Asabella AN: Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biother Radiopharm 2014;29:1-11.
69. Coleman R, Body JJ, Aapro M, et al.; on behalf of the EGWG: Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014;25 (suppl 3):iii124-iii137.
70. Van Poznak CH, Temin S, Yee GC, et al.; American Society of Clinical Oncology: American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-1227.